Ruby Mills sells 33rd-floor space for ₹124.08 crore

Key development: asset sale to Torrent Pharmaceuticals

The Ruby Mills Ltd said on Thursday, August 20, that it has sold its commercial premises on the 33rd floor of its tower project, The Ruby, along with car parking spaces, to Torrent Pharmaceuticals Ltd for ₹124.08 crore. The company disclosed that the agreement for sale was entered into on August 19, 2026. It also said August 19 was the expected date of completion of the sale. The announcement positions the transaction as a large non-operational cash inflow for the listed company.

What exactly was sold

According to the company’s disclosure, the asset is a vacant commercial premises located on the 33rd floor of The Ruby, together with car parking spaces. Because the premises were vacant, Ruby Mills said details relating to the asset’s contribution to turnover, revenue, income, and net worth are not applicable. The company did not link the sale to any operational change, and the disclosure was framed as an asset monetisation event.

Deal value and why the number matters

The consideration for the transaction is ₹124.08 crore. The reported sale value is larger than the company’s Q1 FY27 consolidated revenue of ₹91.5 crore, as highlighted in the market snapshot provided with the update. That comparison underscores the size of the cash inflow relative to a single quarter’s reported top line. At the same time, the company clarified that this is a property sale and not an operating revenue event.

Timeline: agreement date and completion expectation

Ruby Mills stated that the agreement for sale was entered into on August 19, 2026. The same date was also described as the expected completion date. The disclosure, as presented, indicates that signing and expected completion were aligned on the same day, suggesting a transaction structured to close quickly. The company did not provide additional milestones or conditions in the provided text.

Related-party and governance disclosures

Ruby Mills said the buyer, Torrent Pharmaceuticals Ltd, does not belong to the promoter, promoter group, or group companies of The Ruby Mills. It added that the transaction does not constitute a related party transaction. This matters for investors because related-party transactions can raise questions around pricing and governance, and the company explicitly positioned this deal as independent of such concerns.

Not part of a restructuring or scheme

The company said the sale is outside any Scheme of Arrangement and is independent of any restructuring. It also stated that disclosures relating to a slump sale are not applicable. These points indicate the transaction was communicated as a straightforward asset sale rather than a transfer of a business undertaking or a court or regulator-linked restructuring exercise.

Company profile and business context

Ruby Mills is a listed company engaged in manufacturing cotton and blended fabrics. The company’s registered office is at Dadar in central Mumbai. The update also references its real estate asset, The Ruby, which is where the sold 33rd-floor premises is located. The sale highlights the continuing relevance of real estate and related assets within the broader profile of the company.

Market reaction: stock ends marginally higher

On the trading day referenced in the update, shares of The Ruby Mills Ltd ended at ₹412.80 on the BSE. The close was up by ₹1.15, or 0.28%. The move suggests a modest positive reaction as the market digested the disclosed proceeds from the asset sale.

Snapshot table: facts disclosed

Market impact and what investors can take away

The most direct market-relevant element is the size of the proceeds: ₹124.08 crore. As disclosed, the asset was vacant, so the company did not attribute any turnover or income contribution to it, and therefore framed no operational impact from losing the space. The comparison to Q1 FY27 consolidated revenue of ₹91.5 crore signals that the transaction is significant in cash terms relative to recent quarterly reported revenue, even though it is not part of core textile operations. Investors will typically focus on how such proceeds affect the company’s cash position and balance sheet, but the provided disclosure stops at the transaction details and related governance statements.

Conclusion

Ruby Mills has announced the sale of a vacant 33rd-floor commercial premises at The Ruby, along with parking spaces, to Torrent Pharmaceuticals for ₹124.08 crore, with the agreement dated August 19, 2026. The company emphasised that the buyer is not connected to its promoter group, and that the deal is not a related party transaction. It also said the sale is independent of any scheme of arrangement or restructuring, with slump sale disclosures not applicable. Market participants are likely to track any subsequent company communication on the utilisation of proceeds, if disclosed in future filings.